Suspicious activity reporting
Suspicious activity reporting in Healthcare & Life Sciences sits at the intersection of anti-money laundering obligations and sector-specific fraud controls, with the U.S. Department of Health and Human Services Office of Inspector General, the Financial Crimes Enforcement Network, and the U.S. Department of Justice all holding enforcement authority over different layers of the same compliance stack. FinCEN's existing SAR filing requirements apply to healthcare entities that qualify as financial institutions under the Bank Secrecy Act, while OIG advisory opinions and fraud alert guidance shape how compliance teams define and escalate suspicious conduct internally. The practical result: many organizations are running two parallel SAR-adjacent workflows with different triggers, timelines, and escalation paths.
Watch
- FinCEN SAR filing thresholds: whether the $5,000 transaction floor applies to your entity type
- OIG fraud alerts naming specific billing and referral patterns as SAR-reportable conduct
- DOJ False Claims Act settlements where delayed internal escalation factored into penalty calculations
- State-level Medicaid fraud control unit reporting mandates that run parallel to federal SAR obligations
Recent material activity in Healthcare & Life Sciences
Active monitoring in place across Healthcare & Life Sciences. Material developments related to suspicious activity reporting will appear here as they are published.